• PharmAla Biotech received U.S. Patent 12,679,817 covering enantioselective manufacturing processes for (R)- and (S)-enantiomers of MDMA and MBDB.
• Patent targets direct production of single enantiomers, aiming to improve commercial-scale yield and cost versus racemic production.
• Company expects the processes to support economical production of R-MDMA and its non-racemic MDMA candidate ALA-002.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmala Biotech Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608210700PRIMZONEFULLFEED9813949) on August 21, 2026, and is solely responsible for the information contained therein.